CEL-SCI Announces Robert Watson Joins Its Board of Directors
18 December 2017 - 11:30PM
Business Wire
CEL-SCI Corporation (NYSE American: CVM) announced today
that healthcare information technology executive Robert Watson has
joined the Company’s Board of Directors.
Mr. Watson has over 35 years of experience in the healthcare IT
industry as a CEO, board member and advisor to multiple companies.
Having participated in over 75 acquisitions, he has raised nearly
$750,000,000 in capital, completed three public offerings and
successfully sold four companies.
Currently, Mr. Watson is President of the Preparedness
Technology Division at Intermedix. Prior, he was the President and
Chief Growth Officer of NantHealth, and CEO of Streamline Health,
both NASDAQ listed companies. He has held executive positions at
numerous other healthcare IT companies.
Mr. Watson holds an MBA from the Wharton School of Business at
the University of Pennsylvania and a BA from Syracuse
University.
“I am excited to join CEL-SCI’s board at this time, as the
Company approaches evaluating the endpoint of its Phase 3 results,
which may lead to a new and much needed immunotherapy to treat head
and neck cancer. The impact CEL-SCI and its investigational
immunotherapy Multikine* can have in the cancer treatment market
and in improving the quality of life of patients living with the
disease may be enormous. I am pleased to contribute my expertise in
supporting CEL-SCI,” stated Robert Watson.
“We are so pleased that Robert has joined our board. He brings a
depth of knowledge and experience that we believe will add
significant value to our board and our Company. His experience
encompasses executive leadership at large public companies and the
start-up, growth and sale of healthcare companies, as well as
investment banking. We welcome him to our board,” CEL-SCI CEO Geert
Kersten added.
About CEL-SCI Corporation
CEL-SCI is a Phase 3 cancer immunotherapy company. When it comes
to cancer immunotherapy, CEL-SCI believes it is most logical to
boost the patient’s immune system while it is still intact in order
to have the greatest possible impact on survival. Therefore,
CEL-SCI treats patients who are newly diagnosed with head and neck
cancer with its lead investigational immunotherapy Multikine,
BEFORE they have received surgery, radiation and/or chemotherapy.
This approach is unique. Most other cancer immunotherapies are used
only after conventional therapies have been tried and/or failed.
Head and neck cancer represents about 6% of all cancers. Multikine
has received Orphan Drug designation from the FDA for the treatment
of head and neck cancer patients with advanced squamous cell
carcinoma.
The Company’s LEAPS technology is being developed as a
therapeutic vaccine for rheumatoid arthritis and is supported by
grants from the National Institutes of Health. CEL-SCI has patents
on Multikine from the US, Europe, China, and Japan.
The Company has operations in Vienna, Virginia, and in/near
Baltimore, Maryland.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. When used in this press release, the words "intends,"
"believes," "anticipated," "plans" and "expects," and similar
expressions, are intended to identify forward-looking statements.
Such statements are subject to risks and uncertainties that could
cause actual results to differ materially from those projected.
Factors that could cause or contribute to such differences include,
an inability to duplicate the clinical results demonstrated in
clinical studies, timely development of any potential products that
can be shown to be safe and effective, receiving necessary
regulatory approvals, difficulties in manufacturing any of the
Company's potential products, inability to raise the necessary
capital and the risk factors set forth from time to time in
CEL-SCI’s filings with the Securities and Exchange Commission,
including but not limited to its report on Form 10-K and 10-K/A for
the year ended September 30, 2016. The Company undertakes no
obligation to publicly release the result of any revision to these
forward-looking statements which may be made to reflect the events
or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.
* Multikine (Leukocyte Interleukin, Injection) is the trademark
that CEL-SCI has registered for this investigational therapy, and
this proprietary name is subject to FDA review in connection with
the Company's future anticipated regulatory submission for
approval. Multikine has not been licensed or approved for sale,
barter or exchange by the FDA or any other regulatory agency.
Similarly, its safety or efficacy has not been established for any
use. Moreover, no definitive conclusions can be drawn from the
early-phase, clinical-trials data involving the investigational
therapy Multikine. Further research is required, and early-phase
clinical trial results must be confirmed in the Phase 3 clinical
trial of this investigational therapy that is in progress.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171218005344/en/
CEL-SCI CorporationGavin de Windt, 703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2024 to May 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From May 2023 to May 2024